Table 6 Comparisons of treatment outcomes between Adv and Non-Adv group
Variables | Adv (n = 67) | Non-Adv (n = 184) | Total (n = 251) | P value |
|---|---|---|---|---|
Initial antibiotics regimen | 0.781 | |||
3rd cephalosporin plus azithromycin | 65 (97.0) | 178 (96.7) | 243 (96.8) | |
Respiratory quinolone | (−) | 1 (0.5) | 1 (0.4) | |
Piperacillin/tazobactam plus quinolone | 1 (1.5) | 4 (2.2) | 5 (2.0) | |
Piperacillin/tazobactam | (−) | 1 (0.5) | 1 (0.4) | |
Carbapenem | 1 (1.5) | (−) | 1 (0.4) | |
Treatment regimen change (Antibiotics escalation) | 47 (70.1) | 50 (27.2) | 97 (38.6) | 0.024 |
Duration of antibiotics use, day | 12.32 ± 2.76 | 11.64 ± 2.89 | 11.85 ± 2.83 | 0.114 |
Mean antipyretics dose at admission, gram | 5.52 [3.45–6.91] | 4.30 [3.14–6.55] | 4.85 [3.21–6.75] | 0.032 |
Duration of antipyretics use, days | 10.5 ± 2.7 | 10.6 ± 3.1 | 10.6 ± 3.0 | 0.892 |
Adverse event after antipyretics use | 0.005 | |||
Hypotension | 10 (14.9) | 4 (2.2) | 14 (5.6) | |
GI trouble | 6 (9.0) | 2 (1.1) | 8 (3.2) | |
Skin rash | 1 (1.5) | (−) | 1 (0.4) | |
Elevated liver enzyme | 4 (6.0) | 2 (1.1) | 6 (2.4) | |
Length of hospital stay | 15.0 ± 2.3 | 14.8 ± 2.1 | 14.9 ± 2.2 | 0.407 |
Time from admission to improvement of discomfort, day | 4.3 ± 2.8 | 2.9 ± 1.8 | 3.2 ± 2.0 | 0.034 |
In-hospital mortality | 0 (0) | 0 (0) | 0 (0) | > 0.999 |